Skip to main content
Premium Trial:

Request an Annual Quote

SkylineDx, VIB Form Molecular Diagnostics Partnership

NEW YORK — SkylineDx said on Wednesday that it is collaborating with Belgian life science research institute VIB to develop novel molecular diagnostics for unmet medical needs.

According to SkylineDx, the three-year partnership will bring together VIB's single-cell analysis and biomarker discovery expertise with SkylineDx's global network of clinical centers and physicians, as well as its diagnostic development and commercialization know-how.

The alliance will focus on high-potential in vitro diagnostic opportunities for unmet medical needs for global markets, SkylineDx said. Financial and other terms of the deal were not disclosed.

Rotterdam-based SkylineDx currently markets the Merlin assay, which is designed to predict the risk of metastasis in a patient's sentinel lymph nodes, and the MMprofiler test for multiple myeloma prognosis. Both are available as CE-IVD-marked kits in Europe and as CLIA-validated laboratory-developed tests in the US. It also offers a biomarker discovery service.

In early 2020, SkylineDx began working with BioInvent International to characterize predictive immunological signatures for cancer.

The Scan

Call for a Different Tack

Experts weigh the value of recent experiments testing genetically modified pig kidneys using brain-dead individuals, according to Nature News.

Wastewater Warning

The New York Times reports that wastewater surveillance in some parts of the US point to a possible surge.

Can't Get in the Program

Due to the Northern Ireland protocol dispute, the European Union is preventing UK researchers from joining the Horizon Europe research program, the Times of London reports.

Science Paper on Spatial-Controlled Genome Editing

In Science this week: approach to enable a CRISPR-Cas13a-based system to be used as a cancer therapy.